Chondrosarcoma: the decisions you may face

Cancer page →Second-opinion finder →

5 treatment settings, 5 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Other settings

Atypical cartilaginous tumour of the limbs

3 options

Intralesional curettage with local adjuvant, or observation of asymptomatic lesions; no chemotherapy or radiotherapy.

The options, in plain words

Limb-salvage surgery and endoprosthetic reconstructionStandard of care

Removing a bone or soft-tissue sarcoma while keeping the arm or leg, rebuilding with metal implants, bone grafts or growing prostheses in children.

Preserves function without compromising survival
Custom implants for pelvis and spine

Active surveillanceStandard of care

For low-risk prostate cancer, monitoring with PSA, MRI, and repeat biopsy instead of treating, because most such cancers never cause harm.

Avoids incontinence and erectile dysfunction of treatment in men who would never be harmed
Level-1 evidence of safety (ProtecT)

MRIStandard of care

MRI uses a strong magnet and radio waves, with no ionising radiation, to picture soft tissue in finer contrast than CT, so it is the standard scan for brain tumours, prostate, rectal cancer staging, liver lesions and breast screening in high-risk women. It is slow, expensive and blurred by movement.

No ionising radiation
Best soft-tissue and brain imaging
Functional sequences (diffusion, perfusion)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Limb-salvage surgery and endoprosthetic reconstruction

Implant infection and mechanical failure over decades
Requires specialist sarcoma centres

Active surveillance

Anxiety and adherence
Repeat biopsies
Under-used outside high-income countries

MRI

Slow and expensive
Motion artefacts
Gadolinium concerns in renal impairment

Questions to ask about this decision

Between Limb-salvage surgery and endoprosthetic reconstruction, Active surveillance and MRI, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (atypical cartilaginous tumour of the limbs), which of the standard options do you recommend and why?
Why: Guideline options include: Intralesional curettage with local adjuvant, or observation of asymptomatic lesions; no chemotherapy or radiotherapy.

Add these to your appointment list, or take the full question set for this cancer.

Early / localised

Conventional grade 2 to 3, resectable

2 options

Wide en bloc resection with limb-salvage or pelvic reconstruction in a bone sarcoma centre; radiotherapy only for positive margins.

The options, in plain words

Limb-salvage surgery and endoprosthetic reconstructionStandard of care

Removing a bone or soft-tissue sarcoma while keeping the arm or leg, rebuilding with metal implants, bone grafts or growing prostheses in children.

Preserves function without compromising survival
Custom implants for pelvis and spine

IMRT / IGRT (modern external beam)Standard of care

IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.

Conformal dose, fewer side effects
Hypofractionation saves visits

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Limb-salvage surgery and endoprosthetic reconstruction

Implant infection and mechanical failure over decades
Requires specialist sarcoma centres

IMRT / IGRT (modern external beam)

Low-dose bath to normal tissue
Motion management

Questions to ask about this decision

Between Limb-salvage surgery and endoprosthetic reconstruction and IMRT / IGRT (modern external beam), which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (conventional grade 2 to 3, resectable), which of the standard options do you recommend and why?
Why: Guideline options include: Wide en bloc resection with limb-salvage or pelvic reconstruction in a bone sarcoma centre; radiotherapy only for positive margins.

Add these to your appointment list, or take the full question set for this cancer.

Early / localised

Skull base and spine, incompletely resectable

3 options

Maximal safe surgery followed by high-dose proton or carbon-ion radiotherapy.

The options, in plain words

Proton therapyEstablished

Radiation using protons, which stop inside the tumour instead of passing through, so tissue behind it gets no dose.

No exit dose; lower integral dose
Reduced second cancers in children

Carbon-ion therapyEstablished

Heavier charged particles that kill even radiation-resistant tumours, available at only a handful of centres worldwide.

Effective in radioresistant tumours

IMRT / IGRT (modern external beam)Standard of care

Conformal dose, fewer side effects
Hypofractionation saves visits

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Proton therapy

Cost
Range uncertainty
Limited randomised evidence in adults

Carbon-ion therapy

Very few facilities
Cost

IMRT / IGRT (modern external beam)

Low-dose bath to normal tissue
Motion management

Questions to ask about this decision

Between Proton therapy, Carbon-ion therapy and IMRT / IGRT (modern external beam), which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (skull base and spine, incompletely resectable), which of the standard options do you recommend and why?
Why: Guideline options include: Maximal safe surgery followed by high-dose proton or carbon-ion radiotherapy.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Dedifferentiated and mesenchymal

3 optionsCompare side by side →

Surgery plus osteosarcoma-type (doxorubicin, cisplatin) or Ewing-type (doxorubicin, ifosfamide) chemotherapy, benefit uncertain.

The options, in plain words

DoxorubicinApprovedCytotoxic chemotherapy (anthracycline)

The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.

CisplatinApprovedCytotoxic chemotherapy (platinum)

Cisplatin is the original platinum chemotherapy, discovered by accident in 1965; it cures testicular cancer and makes radiation work better in cervical and head and neck cancer.

IfosfamideApprovedCytotoxic chemotherapy (alkylating agent)

Ifosfamide is an alkylating chemotherapy partnered with doxorubicin in sarcoma and with etoposide in Ewing sarcoma, given with a bladder-protecting drug.

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Doxorubicin all recorded rates →

Cumulative dose: risk rises steeply above 400-550 mg/m² (see the anthracycline calculator).
Reduce by 50% for bilirubin 20-50 µmol/L and 75% for 50-85 µmol/L.

Cisplatin all recorded rates →

Dose reduce or avoid for CrCl below 60 (carboplatin is the alternative).

Questions to ask about this decision

Between Doxorubicin, Cisplatin and Ifosfamide, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (dedifferentiated and mesenchymal), which of the standard options do you recommend and why?
Why: Guideline options include: Surgery plus osteosarcoma-type (doxorubicin, cisplatin) or Ewing-type (doxorubicin, ifosfamide) chemotherapy, benefit uncertain.
Am I a candidate for Doxorubicin, Cisplatin, Ifosfamide, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Advanced, first line

Advanced IDH1-mutant conventional

2 options

Ivosidenib within the CHONQUER phase 3 trial or compassionate access; no approved systemic therapy.

The options, in plain words

IvosidenibApprovedSmall-molecule IDH1 inhibitor

The first drug to block a mutant metabolic enzyme in cancer. With azacitidine it tripled survival in IDH1-mutated AML that could not take intensive chemotherapy.

IDH inhibitorsApproved

Pills that block mutant IDH1 or IDH2 enzymes, which flood cells with a metabolite that blocks maturation; approved in leukaemia, bile duct cancer and low-grade glioma.

Oral, well tolerated
First targeted therapy for IDH-mutant glioma
Approved across leukaemia and solid tumours

The evidence behind it

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen Phase 3 NCT06127407136 peopleevidence 46
Tests Ivosidenib
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
No headline result recorded yet.

The main trade-offs on record

Ivosidenib all recorded rates →

Side effect	Any grade	Grade 3+
Differentiation syndrome · AGILE combination arm	14%	-

Known QT prolongation. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.

Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.

IDH inhibitors

Differentiation syndrome
Isoform switching and second-site resistance
Responses in solid tumours are cytostatic

Questions to ask about this decision

Between Ivosidenib and IDH inhibitors, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
How closely do I match the people in Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen, and does that change what the results mean for me?
Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
Which side effects of Ivosidenib are most likely for me, which are reversible, and which would make us stop?
Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (advanced idh1-mutant conventional), which of the standard options do you recommend and why?
Why: Guideline options include: Ivosidenib within the CHONQUER phase 3 trial or compassionate access; no approved systemic therapy.
Am I a candidate for Ivosidenib, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.